The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
Section snippets
Subjects
Fasting blood samples were obtained from 653 young black females attending postnatal clinics at the Mabvuku Polyclinic and Edith Opperman Maternity Hospital in Zimbabwe. Approval was obtained for these studies from the University of Cape Town Ethics Committee and the Medical Research Council of Zimbabwe and all participants signed written consent.
Analyses
After venesection, blood was promptly processed before freezing plasma and white blood cells for later analysis in batches. Plasma cholesterol and
Results
Genotyping of the two PCSK9 nonsense mutations in the 653 samples revealed that C679X occurred in 3.7% of subjects (n = 24), which included one homozygote (Table 1). This gives an allele frequency of 0.019. None of the 653 subjects carried the Y142X variant. The C679X variant was associated with a 27 percent reduction in LDL–cholesterol and did not influence plasma HDL–cholesterol or triglyceride concentrations. Of interest, the C679X homozygous subject had the lowest LDL–cholesterol out of the
Discussion
Our findings show that the PCSK9 nonsense variant C679X occurs in 3.7% of Zimbabwean blacks and is associated with a 27% reduction in LDL–cholesterol (1.6 ± 0.3 mmol/L versus 2.2 ± 0.7 mmol/L in non-carriers). These results are very similar to those of Cohen et al., who found PCSK9 nonsense mutations occurring in 2.6% of African Americans that were associated with a 28% reduction in LDL–cholesterol [11]. In addition to confirming that this commonly encountered mutation in the PCSK9 gene has a
Acknowledgments
Thanks to Dr. George Mantiri and Ms. Joanna Brisbane for assisting with DNA extractions. This work was supported by grants from the Raine Medical Research Foundation, National Health & Medical Research Council (403908), and National Heart Foundation of Australia (G 139 1155). Thanks to the Lotterywest State Biomedical Genomics Facility, Clinical Department of Immunology and Biochemical Genetics, Royal Perth Hospital, for the use of the ABI 7900HT. Partial support was also obtained from the
References (24)
- et al.
A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32
Am J Hum Genet
(1999) - et al.
Evidence for a third genetic locus causing familial hypercholesterolemia. A non-LDLR, non-APOB kindred
J Lipid Res
(1999) - et al.
Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice
J Lipid Res
(2003) - et al.
Functional characterization of Narc 1, a novel proteinase related to proteinase K
Arch Biochem Biophys
(2003) - et al.
Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver
J Biol Chem
(2004) - et al.
The low density lipoprotein receptor prevents secretion of dense apoB100-containing lipoproteins from the liver
J Biol Chem
(2004) - et al.
Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred
Arterioscler Thromb Vasc Biol
(2000) - et al.
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Nat Genet
(2003) - et al.
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation
Proc Natl Acad Sci USA
(2003) - et al.
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia
Arterioscler Thromb Vasc Biol
(2004)
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment
Proc Natl Acad Sci USA
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
Nat Genet
Cited by (309)
PCSK9 and the nervous system: a no-brainer?
2023, Journal of Lipid ResearchTargeting PCSK9 to tackle cardiovascular disease
2023, Pharmacology and TherapeuticsGene editing for dyslipidemias: New tools to “cut” lipids
2023, AtherosclerosisGuidance for the diagnosis and treatment of hypolipidemia disorders
2022, Journal of Clinical LipidologyFamilial hypobetalipoproteinemia caused by homozygous loss-of-function mutations in PCSK9: A case report
2022, Journal of Clinical LipidologyLDL Cholesterol—How Low Can We Go?
2022, Endocrinology and Metabolism Clinics of North America